European Journal of Nuclear Medicine

, Volume 22, Issue 2, pp 126–131 | Cite as

Comparison of technetium-99m methoxyisobutylisonitrile and gallium-67 citrate scanning in the assessment of lymphomas

  • P. Ziegels
  • M. Nocaudie
  • D. Huglo
  • M. Deveaux
  • L. Detourmignies
  • E. Wattel
  • X. Marchandise
Original Article

Abstract

The aim of this study was to compare the value of scintigraphy using technetium-99m methoxy-isobutylisonitrile (MIBI) with that of scintigraphy using gallium-67 citrate in the assessment of Hodgkin's disease and non-Hodgkin's lymphoma and to relate these results with those of CT scan and MRI. Fifty-eight patients were included either for a follow-up examination or for monitoring of their treatment. Twenty-three residual masses were studied. A whole-body scan was performed, followed by single-photon emission computed tomography (SPET) 20 min after injection of 740 MBq of99mTc-MIBI and 72 h after injection of 185 MBq of67Ga citrate. The overall sensitivity of99mTc-MIBI and67Ga citrate was 71% and 68%, respectively, and the overall specificity was 76% and 44%, respectively. For residual masses, the sensitivity was 44% with both tracers and the specificity was 80% with99mTc-MIBI and 53% with67Ga citrate. The positive predictive values were 85% and 68% and the negative predictive values were 59% and 44%, respectively. The signal-to-background ratio was 1.5 for99mTc-MIBI and 2 for67Ga citrate. At present,99mTc-MIBI cannot replace67Ga citrate in the assessment of lymphomas.

Key words

Technetium-99m methoxyisobutylisonitrile Gallium-67 citrate Hodgkin's disease Non-Hodgkin's lymphoma Residual mas 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Albuquerque L, Baillet G, Delattre J, Chen Q, Poisson M. Tomoscintigraphie cérébrale au MIBI dans la surveillance des tumeurs gliales de l'adulte.J Med Nucl Biophys 1992; 16: 181.Google Scholar
  2. 2.
    Aktolun C, Bayhan H, Celasum B, Kir M. Unexpected uptake of technetium 99m hexakis-2-methoxy-isobutylisonitrile in giant lymph node hyperplasia of the mediastinum (Castelman's disease).Eur J Nucl Med 1991; 18: 856–859.Google Scholar
  3. 3.
    Anderson K, Leonard R, Canellos G, Skarin A, Kaplan W. High-dose gallium in lymphoma.Am J Med 1983; 75: 327–331.Google Scholar
  4. 4.
    Balon H, Fink-Bennett D, Stoffer S. Technetium-22-sestamibi uptake by recurrent Hürthle cell carcinoma of the thyroid.J Nucl Med 1992; 33: 1393–1395.Google Scholar
  5. 5.
    Bares R, Dempke W, Handt S, Galonska P, Buell U, Osieka R, Mittermayer C. Somatostatin receptor scintigraphy (SRS) in malignant lymphoma (ml): first results and comparison with CT and positron-emission tomography (PET) with fluorine-18 labeled deoxyglucose (FDG) [abstract].J Nucl Med 1993; 34: 164.Google Scholar
  6. 6.
    Betz EH, Reznick M. Anatomie pathologique speciale.Sciences et Lettres 1985; 277–290.Google Scholar
  7. 7.
    Brousse N. Classifications histologiques des lymphomes non hodgkiniens in Lymphomes non hodgkiniens. In: Solal-Celigny P, Brousse N, eds. Lymphomes non hodgkiniens. Paris: Frison Roche; 1991: 91–101.Google Scholar
  8. 8.
    Coakley AJ, Kettle A, Wells CP, O'Doherty MJ, Collins R. Technetium-99m-sestamibi: a new agent for parathyroid imaging.Nucl Med Commun 1989; 10: 791–794.Google Scholar
  9. 9.
    Chin M, Kronauge J, Piwnica-Worms D. Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutylisonitile) technetium (1) in cultured mouse fibroblasts.J Nucl Med 1990; 31: 1646–1653.Google Scholar
  10. 10.
    Caner B, Kitapçl M, Unlü M, Erbengi G, Calikoglu T, Gögüs T, Bekdik C. Technetium-99-m-MIBI uptake in benign and malignant bone lesions: a comparative study with technetium-99m MDP.J Nucl Med 1992; 33: 319–324.Google Scholar
  11. 11.
    Carde P, Pfreundschuh M, da Costa L, Manil L, Lumbroso JD, Caillou B, Parmentier C, Saccavini JC, Diehl V. Radiolabeled monoclonal antibodies against Reed-Sternberg cells for in vivo imaging of Hodgkin's disease by immunoscintigraphy.Cancer Res 1989; 117: 101–111.Google Scholar
  12. 12.
    Crane P, Laliberté R, Heminway S, Thoolen M, Orlandi C. Effect of mitochondrial viability and metabolism on technetium99m-sestamibi myocardial retention.Eur J Nucl Med 1993; 20: 20–25.Google Scholar
  13. 13.
    Delmon-Moignon L, Piwnica-Worms D, Van den Abeele A, Holman B. Uptake of the cation hexakis(2-methoxyisobutylisonitrile)-technetium-99m by human carcinoma cell lines in vitro.Cancer Res 1990; 50: 2198–2202.Google Scholar
  14. 14.
    Drossman S, Schiff R, Kronfeld G; McNamara J, Leonidas J. Lymphoma of the mediastinum and neck: evaluation with Ga67 imaging and CT correlation.Radiology 1990; 174: 171–175.Google Scholar
  15. 15.
    Dudley J, Pennell R, Underwood D, Costa C, Ell PJ.Thallium myocardial perfusion tomography in clinical cardiology. Berlin Heidelberg New York: Springer, 1992.Google Scholar
  16. 16.
    Front D, Ben-Haim S, Israel O, Epelbaum R, Haim N, Even-Sapir E, Kolodny G, Robinson E. Lymphoma: predictive value of Ga-67 scintigraphy after treatment.Radiology 1992; 182: 359–363.Google Scholar
  17. 17.
    Front D, Bar-Shalom R, Epelbaum R, Haim N, Ben-Arush M, Ben-Shalar M, Gorenberg M, Kleinhaus U, Parmett S, Kolodny M, Israel M. Early detection of lymphoma recurrence with gallium-67 scintigraphy.J Nucl Med 1992; 34: 2101–2104.Google Scholar
  18. 18.
    Frija J, Bris C, Yarner C, et al. MRI with gadolinum of post therapeutic residual masses in lymphoma [Suppl abstract].Eur Radiol 1991; 1: 17.Google Scholar
  19. 19.
    Gamsu G, Sostman D. Magnetic resonance imaging of thorax.Am Rev Respir Dis 1989; 139: 254–274.Google Scholar
  20. 20.
    Gasparini M, Balzarini L, Castellani, Tesoro Tess J, Maffioli L, Petrillo R, Ceglia E, Musume CIR, Buraggi G. Current role of gallium scan and magnetic resonance imaging in the man agement of mediastinal Hodgkin lymphoma.Cancer 1993; 72: 577–582.Google Scholar
  21. 21.
    Gisselbrecht C. Maladie de Hodgkin. Epidémiologie, étiologie, diagnostic, évolution et pronostic, principes du traitement.Rev Prat (Paris) 1989; 39: 15.Google Scholar
  22. 22.
    Kao C, Wang S, Lin W Hsu C, Liao S, Yeh S. Detection of nasopharyngeal carcinoma using 99mTc-methoxyisobutylisonitrile SPECT.Nucl Med Commun 1993; 14: 42–46.Google Scholar
  23. 23.
    Hassan I, Sahweil A, Constantinides C, Mahmoud A, Nair M, Omar Y, Abdel-Dayem H. Uptake and kinetics of Tc-99m hexakis 2-methoxy isobutyl isonitrile in benign and malignant lesions in the lungs.Clin Nucl Med 1989; 14: 333–340.Google Scholar
  24. 24.
    Hayes R. The medical use of gallium radionuclides: a brief history with some comments.Semin Nucl Med 1978; 8: 183–191.Google Scholar
  25. 25.
    Hesslewood S, Leung E. Drug interactions with radiopharmaceuticals.Eur J Nucl Med 1994; 21: 348–356.Google Scholar
  26. 26.
    Hill M, Cunningham D, McVicar D, Roldan A, Husband J, McCready R, Mansi J, Milan S, Hickish T. Role of magnetic resonance imaging in predicting relapse in residual masses after treatment of lymphoma.J Clin Oncol 1993; 11: 2273–2278.Google Scholar
  27. 27.
    Horn N, Ray G, Kriss J. Gallium-67 citrate scanning in Hodgkin's disease and non-Hodgkin's lymphoma.Cancer 1976; 37–250.Google Scholar
  28. 28.
    Kostakoglu L, Abdel-Dayen H, Brien J, Castellino R, Hilton S, Larson S. Assessment of intermediate grade lymphoma (IGL) with a new tumor imaging agent, “Tc-99m sestambi” [abstract].Eur J Nucl Med 1992; 19: 579.Google Scholar
  29. 29.
    Kostakoglu L, Yeh S, Portlock C, Heelan R, Yao t-J, Niedzwiecki D, Larson ST. Validation of gallium-67-citrate single photon emission computed tomography in biopsy confirmed residual Hodgkin's disease in mediastinum.J Nucl Med 1992; 33:345–350.Google Scholar
  30. 30.
    Krening E, Kwekkeboom D, Bakker W Breman W Kooij P, Oei H, van Hagen M, Postema P, de Jong M, Reubi J, Visser T, Reijs A, Hofland L, Koper J, Lamberts S. Somatostatin receptor scintigraphy with111In-DTPA-D-Phe- and123I-Tyr-3-octreotide: the Rotterdam experience with more than 1000 patients.Eur J Nucl Med 1993; 20: 716–731.Google Scholar
  31. 31.
    Larson S. Mechanism of localisation of gallium-67 in tumors.Semin Nucl Med 1978; 8: 193–203.Google Scholar
  32. 32.
    Mehta B, Rosa E, Fissekis J, Bading J, Bielder J, Larson S. In-vivo identification of tumor multidrug resistance with tritium-3-colchicine.J Nucl Med 1992; 33: 1373–1377.Google Scholar
  33. 33.
    Müller S, Guth-Tougelides B, Creutzig H. Imaging of malignant tumors with Tc-99m-MIBI [abstract].J Nucl Med 1987; 28: 562.Google Scholar
  34. 34.
    Müller S, Reiners C, Paas M, Guth-Tougelidis B, Budach V, Konietzko N, Alberti W. Tc-99m-MIBI and T1-201 uptake in bronchial carcinoma [abstract].Eur J Nucl Med 1989; 30: 845.Google Scholar
  35. 35.
    Nyman R, Rehn S, Glimelius B, Hagberg H, Heramingsson A, Jung B. Magnetic resonance imaging for assessment of treatment effects in mediastinal Hodgkin's disease.Acta Radiol 1987; 28: 145–151.Google Scholar
  36. 36.
    Piwnica-Worms D, Holman B. Editorial: non-cardiac application of hexakis-(alkylisonitrile) technetium-99m complexes.J Nucl Med 1990; 31: 1166–1167.Google Scholar
  37. 37.
    Piwnica-Worms D, Chin ML, Croop J, Kromauge J. Enhancement of Tc-99m-Sestamibi accumulation in multidrug resistant (MRD) cells by cytotoxic drugs and MRD reversing agents [abstract].J Nucl Med 1993; 34: 140.Google Scholar
  38. 38.
    Rao V Chiu M, Kronauge J, Piwnica-Worms D. Expression of recombinant human multidrug resistance P-glycoprotein in insect cells confers decreased accumulation of technetium-99msestamibi.J Nucl Med 1994; 35: 510–515.Google Scholar
  39. 39.
    Surbone A, Longo L. Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management.J Clin Oncol 1988; 6: 1832–1837.Google Scholar
  40. 40.
    Tredaniel J, Lepage E, Frija J. Les masses résiduelles après chimiothérapie des lymphomes non Hodgkiniens.Nouv Rev Hematol 1988; 30: 75–77.Google Scholar
  41. 41.
    Turner D, Fordham E, Ali A, Slayton R. Gallium-67 imaging in the management of Hodgkin's disease and other malignant lymphomas.Semin Nucl Med 1978; 8: 205–218.Google Scholar
  42. 42.
    Vanhagen P, Krenning E, Reubi J, Mulder A, Bakker W Oei H, Löwenberg B, Lambert S. Somatostatin analogues scintigraphy of malignant lymphomas.Br J Haematol 1993; 83: 75–79.Google Scholar

Copyright information

© Springer-Verlag 1995

Authors and Affiliations

  • P. Ziegels
    • 1
  • M. Nocaudie
    • 1
  • D. Huglo
    • 1
  • M. Deveaux
    • 1
  • L. Detourmignies
    • 2
  • E. Wattel
    • 2
  • X. Marchandise
    • 1
  1. 1.Service Associé de Médecine NucléaireHôpital CI. Huriez, Chu de LilleLilleFrance
  2. 2.Service des Maladies du SangHôpital CI. Huriez, Chu de LilleLilleFrance

Personalised recommendations